Someone You Should Know: The Relentless Pledge – KSFY

SIOUX FALLS, S.D. (Dakota News Now) - A Mitchell boy is defying one of the darkest times in his family's life, his dad's battle with cancer. He's turning it into a message of inspiration for others.

On that exact day maybe three hours later, that's when I started going door to door.

Floyd Korzan is a motivated kid. That's easy to see. It's also evident that he's caring and loves his dad very much.

"I remember some nights, they'd literally bring over a bed and I'd just sleep with him there.

His dad Matt spent a lot of time at the Mayo Clinic in Rochester, Minnesota battling leukemia from 2012 to 2017. It came back twice.

"The doctors at the Mayo Clinic told our family that the only thing more deadly than leukemia is relapsed leukemia, said Matt.

But Matt was relentless in his fight, a keyword in their family to this day.

"I'm a high-energy guy, this was crushing and devastating, said Matt. I'd never been sick a day in my life before this happened, it was crazy. But, my mindset is you got to be relentless. That's what I told Floyd. You got to fight, you got to get up, and you got to gut it out, you've got to be relentless.

Now that Matt has made it more than two years cancer-free thanks to a stem cell transplant they're doing something special.

But the impact it's had already, they did not expect.

Less than a month ago, Floyd, who's just 13 years old, started a nonprofit with his parents' help.

Its centered on that word, relentless.

"After I saw what struggle me, my dad and the rest of my family went through, I thought that that would've been a great motivator for some people to try to achieve their goals and overcome obstacles, said Floyd.

People can go online and take the relentless pledge, purchase a wristband, or nominate someone in their community to receive one for free whether that's a cancer patient or local heroes like police and firefighters.

"They have to risk their lives almost every day just to try to help people and I feel like that takes some relentlessness, said Floyd.

The Korzans have a website and social media pages for their relentless pledge. Thanks to the reach of their Facebook, it's already become a global movement.

"Floyd has had pledges and we've shipped these relentless wristbands to folks in 36 different states and three continents, these are people we've never heard of, we've received emails that would make you tear up, I'm really proud of it, said Matt.

Their goal is big.

"The goal is to get our relentless wristbands to every single cancer patient in America, said Matt.

But then again, they have a plan.

"To be relentless.

See the original post:
Someone You Should Know: The Relentless Pledge - KSFY

Stem Cell and Primary Cell Culture Medium Market: Size, Share, Analysis, Region – News by aeresearch

Latest Market Research Report on Stem Cell and Primary Cell Culture Medium Market size | Industry Segment by Applications (Biopharmaceutical Manufacturing, Tissue Engineering & Regenerative Medicine, Gene Therapy and Other), by Type (Liquid Media and Powder Media), Regional Outlook, Market Demand, Latest Trends, Infrared Temperature Measurement Instruments Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025. Analyzes current market size and upcoming 5 years growth of this industry.

A basic outline of the competitive landscape:

This research report delivers a collective study on the Stem Cell and Primary Cell Culture Medium Industry, that also contains an intricate valuation of this business vertical. Also, segments of the Stem Cell and Primary Cell Culture Medium market have been clearly explained in this report, in addition to a basic overview of this market with respect to its present-day status as well as market size, in terms of returns and volume parameters.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/62644

A crisp outline of the market segmentation:

The report is a pervasive account of the important insights regarding the regional spectrum of this industry as well as the companies that have effectively established their standing in the Stem Cell and Primary Cell Culture Medium market.

How far does the scope of the Stem Cell and Primary Cell Culture Medium market traverse?

A complete outline of the regional spectrum:

Key Questions Answered in this Report

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/62644

Read the rest here:
Stem Cell and Primary Cell Culture Medium Market: Size, Share, Analysis, Region - News by aeresearch

At NSUH, a cell of the century in the Don Monti unit – Innovate Long Island

By GREGORY ZELLER //

That light at the end of the tunnel comes from the Northwell Health Cancer Institute, which provided hope and bona fide bone marrowy health improvements to a record number of patients last year.

As 2019 ticked down, staffers of the NHCIs Don Monti Adult Stem Cell Transplant Program gathered inside North Shore University Hospitalto recognize what Ruthee Lu-Bayer, chief of the Don Monti Bone Marrow Transplantation Unit, called a monumental milestone: the units 100th stem cell transplant of the year.

While any cancer clinic worth its salt is going to embrace hope, joy can be a rare commodity but the 100th stem cell transplant of 2019 triggered a full-on celebration at the Manhasset hospital, where stem cell transplants began in 1987 and are now performed in the 10-bed, inpatient Don Monti unit.

Complete with balloons, cake and a salute to No. 100 herself cancer-battling patient Teresa OHalloran the celebration assembled the units myriad doctors, nurses and other professionals, with Bayer applauding the combined efforts of every member of our staff who made this moment happen.

I always say that getting through their diagnosis is half the battle, the board-certified medical oncologist noted. When our patients arrive for transplant, I ask them to think of their transplant date as their second birthday, a time when they can begin to live their lives again.

Century mark: Don Monti Bone Marrow Transplantation Unit chief Ruthee Lu-Bayer and No. 100, Teresa OHalloran.

The gathering was also a celebration of the patients themselves, Bayer added, including OHalloran, whos fighting back against adult acute myeloid leukemia, a type of cancer in which the bone marrow produces abnormal white blood cells.

The 62-year-old East Islip resident, known affectionately as No. 100 around the unit, received the tough diagnosis last August and was admitted to NSUH in December for a bone marrow transplant. Following several days of preparatory chemotherapy, she received her infusion as the calendar flipped to 2020 and is now making an unusually rapid recovery, according to Northwell Health.

OHalloran, who joined the celebration from the safety of her isolated recovery room, credits her faith and positive outlook Ive always looked at the glass as half full, she noted and urged potential stem cell donors to check in with Be The Match, the national, nonprofit marrow-donor program.

I wish everyone could understand how important it is to be tested as a possible match, OHalloran added. Its a simple cheek swab and you could wind up saving someones life.

Visit link:
At NSUH, a cell of the century in the Don Monti unit - Innovate Long Island

Please Quit Telling Me It’s Not The Cancer – Curetoday.com

A cancer survivor talks about the side effects of cancer and chemo few people truly understand.

She has myelodysplastic syndrome, which is rare, and would love to communicate with others who have MDS.

However, I monitor any additional medical problems that I did not have before my cancer diagnosis. If it pops up afterward, there may be a reason. It is time to get online and to talk to my doctor about whether it is related to my cancer or treatment.

Recently, a friend came to my book club bruised from a fall after two stem cell implants. I asked her if anyone had told her chemo, every kind of chemo, can cause balance problems and she said no. No one told me either, and I found out from a trainer at the YMCA. I couldnt understand why when I leaned over to pick something up I would pitch forward. Physical therapy and personal training can assist with this, but we need to know first. This information should be given to every single cancer patient.

I had become increasingly irritated with people at my dentist's office telling me that having one tooth after another crack causing an extraction is due to my hard bite. A hygienist told me airily I had the hardest bite of any patient in the office!

Yes, I am nervous and grind my teeth, I do have bruxism, but to have 5 teeth removed in one year in 2019 is excessive! Finally, my oncologist shared with me that one of the chemos I was on weakens the bone structure. My dentist, who is wonderful, also researched and told me the same thing years after my diagnosis.

My audiologist originally thought my severe drop in hearing loss was due to Presbycusis or aging. I brought in an earlier audiogram to compare the precipitous drop. I then did some research proving the chemo I was on could because hearing loss. She was shocked and immediately went to work to help me.

I started suffering severe stomach pains and my oncologist referred me to a gastroenterologist. He did an endoscopy, found esophageal ulcers, and put me on medication. My PCP tried to tell me it was my age since he knew several patients with this problem. I did not believe him, because I never had problems before. Later the nurse practitioner for the specialist told me that cancer often does cause the ulcers. Again, my research also mentioned any compromised immune system problem such as cancer can lead to this problem that I used to start this conversation.

And, speaking of age, please do not tell me you know how I feel, because you are slowing down from age. Yes I get that and admit as an elderly person it takes me much longer to complete tasks. We all get more tired as we get older. However, that is not the same as the type of fatigue cancer survivors have, where we can be fine and suddenly drop and have to take to bed immediately.

Being forgetful is also part of old age and I know that, but that search for words known to every one of us with chemo brain is scary!

Many cancer survivors experience secondary cancers, total joint replacements from the bone density being reduced and countless other problems from the diseases or treatment. Sometimes it is not cancer-related. Joints do wear out. I have severe arthritis and had a rotator cuff surgery long before my cancer hit. The shoulder is worse now, but it is from gulp age! Our immune systems are affected by cancer too. We may get more frequent infections and need to watch carefully not to be around people who are sick.

Some people may ask if it really matters whether it is related to cancer or not. For us it does. My excellent audiologist keeps in touch with my oncologist and we monitor my remaining hearing. It was my oncologist who referred me to the specialist for the esophageal ulcers. The oncologist is truly unique because they work with so many specialists and family practitioners.

I ask myself why the doctors didnt tell me these side effects. It would take them all day to go over the possible side effects and scare the heck out of us. There are many side effects we will never have. However, it is up to us to know our bodies and to be vigilant in monitoring them. Cancer is an insidious and systematic disease and doesnt affect just one part of our body. However, by having a great relationship with our doctors, doing some basic research to start a dialogue with our doctors, and talking to other survivors, we can help ourselves.

It does not help to become paranoid and think about this all the time. Go read a book, watch a movie, play with your children and grandchildren and enjoy life. You are doing what you should and are better off for it!

See the article here:
Please Quit Telling Me It's Not The Cancer - Curetoday.com

Renew Stem Cell and Laser is Expanding Its Offering Outside of Scottsdale – Press Release – Digital Journal

Renew Stem Cell and Laser has a reputation for being a top provider of stem cell and laser treatments in Scottsdale. The high caliber clinic is excited to announce that they are currently expanding their service area to reach all of Arizona. Technicians are available to take appointments and give consultations.

Scottsdale, Arizona - Renew Stem Cell and Laser is excited to announce that starting now, clients all over Arizona will be able to enjoy their state of the art facility. The service menu is going to remain the same, for now. However, more clients will have access to the laser and stem cell therapies that Renew Stem Cell and Laser Scottsdale has to offer.

Renew Stem Cell and Laser is expanded their service areas to include all of Arizona, with the hopes of helping more clients. With multiple services available, clients are expected to flock to the facility. It is unclear yet as to if more services are going to be offered in the future. For now, this one of a kind facility is ready to lend a helping hand to customers outside of Scottsdale. Customers currently in Scottsdale do not have to worry about being pushed to the side. There are enough technicians and open appointments for treatments to accommodate an influx of clients.

This med spa in Scottsdale is excited to reach out to new clients who are in need of services. Consultations are currently being offered to new clients who arent sure which services are right for them. The facility promises that the quality of the treatments will not waiver at all, even though more clients are expected to sign up for services. The prices of services will also remain the same because Renew Stem Cell and Laser is a facility that is dedicated to their clients.

The public is urged to check out what this med spa has to offer in terms of services. Renew Stem Cell and Laser is excited to speak with clients about their facial and body treatments, which involve laser therapy. Many clients are ideal for stem cell therapy and dont even know it. Renew Stem Cell and Laser has decided to raise the bar and extend their service area to branch out to new clients. Numerous people in Arizona can now take advantage of everything on the service menu, without any restrictions.

In the past, Renew Stem Cell and Laser focused their services on the Scottsdale area. Now, the med spa is branching out to expand their service area to include all areas of Arizona. More exciting changes are expected for the future of this one of a kind company. The public is only expected to benefit as this facility makes changes towards bettering their services.

Media ContactCompany Name: Renew Stem Cell and LaserContact Person: Dr. Kerry PhelpsEmail: Send EmailPhone: (480) 869-4666Address:9700 N 91st St Suite B-112 City: ScottsdaleState: AZCountry: United StatesWebsite: renewstemcellandlaser.com/

Read the original:
Renew Stem Cell and Laser is Expanding Its Offering Outside of Scottsdale - Press Release - Digital Journal

Stem Cell and Primary Cell Culture Medium Market Analysis And Forecast to 2026 by Recent Trends, Developments in Manufacturing Technology and Regional…

QY Research has lately published a new report titled, *Stem Cell and Primary Cell Culture Medium Market Report 2020 and Forecast to 2026*. The researchers have offered a broad understanding of the industry with the help of research methodologies such as PESTLE Analysis and Porters Five Forces.

Global Stem Cell and Primary Cell Culture Medium Market Outlook to 2026:

The report is just the right resource that global and regional Stem Cell and Primary Cell Culture Medium players and investors need to peep into the future of their business and plan out effective growth strategies. It is a compilation of intelligent and accurate research and analysis studies that help players in the Stem Cell and Primary Cell Culture Medium business to understand the growth patterns of leading segments and regions, nature of competition, and other significant aspects. Buyers of the report are provided with reliable forecasts for total revenue, consumption, sales, CAGR, production, and other important factors.

Click Here For Sample Copy @ https://www.qyresearch.com/sample-form/form/1442345/global-Stem-Cell-and-Primary-Cell-Culture-Medium-market

The company profiling section of the report provides a brilliant analysis of the growth of leading players in the industry, based on share, recent developments, geographical expansion, regional presence, technology, and many other factors. The vendor landscape is also presented in quite some detail in the report.

This report includes the following manufacturers; we can also add the other companies as you want.MerckSTEMCELL TechnologiesIrvinesciCell Applications, IncBiological IndustriesMiltenyi BiotecSwiss Medica ClinicPromocellCreative BiolabsLifeline Cell TechnologyScienCell Research LaboratoriesOsiris TherapeuticsNuVasiveChiesi PharmaceuticalsJCR PharmaceuticalPharmicellMedi-postAnterogenMolmedTakeda (TiGenix)

Market Segment by TypeLiquid MediaPowder Media

Market Segment by ApplicationBiopharmaceutical ManufacturingTissue Engineering & Regenerative MedicineGene TherapyOther

Some Major Table of Contents

Executive Summary: The report begins with a summary of the entire research study, along with CAGR and value or volume forecasts.

Top Segments: As the name suggests, this section gives details about leading and also other segments, their growth potential, share, and other important factors.

Leading Regions: Here, readers are provided with an in-depth study on key regions and countries and their overall growth during the forecast period.

Company Profiling: This section includes a detailed comparison of top Stem Cell and Primary Cell Culture Medium players, accurate analysis of the competitive landscape, and other studies.

Dynamics: Buyers of the report have access to an intelligent research study on crucial drivers, restraints, trends, and opportunities in the Stem Cell and Primary Cell Culture Medium business.

Conclusion: Here, the analysts authoring the report have provided their overall take on the Stem Cell and Primary Cell Culture Medium business and the industry. This section also includes important findings from the research study.

Continued.

Read Full Report with TOC @ https://www.qyresearch.com/index/detail/1442345/global-Stem-Cell-and-Primary-Cell-Culture-Medium-market

What the Report has to Offer?

1. Size Forecasts: The report has analysed the industry based on the value and volume over the projected period. Other important parameters including price, capacity, cost, revenue, gross margin, sales revenue, and production are also looked into

2. Future Prospects: The report sheds light on the lucrative business prospects that may prove promising for the players to make future investment

3. Trend Analysis: The readers will gain an insight into the upcoming trends and developments that may take place in the coming future

4. Segmental Analysis: Segments such as application, product type, and end user, along with their contribution to the overall industry size, are analysed by the researchers in this section

5. Regional Analysis: Here, the report examines the present and upcoming developments in varied regions and respective countries

6. Competitive Analysis: The report here discusses about the key strategic initiatives considered by the key players to sustain their hold. This analysis will surely help the competitors in planning their activities ahead

Contact US:QY Research, INC.17890 Castleton, Suite 218,Los Angeles, CA 91748USA: +1 626 428 8800India: +91 9766 478 224Emails [emailprotected]

Original post:
Stem Cell and Primary Cell Culture Medium Market Analysis And Forecast to 2026 by Recent Trends, Developments in Manufacturing Technology and Regional...

Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals – Yahoo Finance

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today highlighted recent progress across several programs and outlined goals for 2020. These updates will be discussed during a webcast presentation at the 38th annual J.P. Morgan Healthcare Conference on Wednesday, January 15th at 11:30 a.m. PT (2:30 p.m. ET).

"In 2019 we generated landmark data from our ADC-based targeted patient preparation platform, which is delivering a new class of antibody-drug conjugates (ADCs) that have the power to bring one-time treatment to more patients with autoimmune diseases, blood cancers and genetic diseases. We also presented clinical data for our first-line stem cell mobilization program, MGTA-145, which we are developing as the new standard of care for stem cell mobilization with the potential to benefit all of the transplant-eligible patients each year," said Jason Gardner, D. Phil., President and Chief Executive Officer, Magenta. "As we begin 2020, we are particularly excited to unveil our MGTA-117 clinical candidate for targeted patient preparation for stem cell transplant or gene therapy. New results announced today highlight the potency, safety and broad therapeutic index of MGTA-117, well above that of currently approved ADCs. We believe that MGTA-117 is the optimal agent for depleting stem cells to enable safe immune reset. We look forward to moving this program into the clinic with initial clinical data expected in 2021."

Targeted Patient Preparation Programs

Current methods to condition patients before transplant and gene therapy are dependent on toxic, non-specific chemotherapy or radiation. These pre-transplant treatments are associated with significant side effects, including infertility, cancer, organ damage and death. Magenta is developing targeted, disease-modifying ADCs that are designed to precisely and rapidly remove the disease-causing cells in the body and enable immune system reset without the need for chemotherapy or radiation.

CD117-ADC Recent Progress

Data presented at the American Society of Hematology (ASH) annual meeting in December 2019, showed the first-ever successful transplant of gene-modified cells in non-human primates using a CD117-targeted, single-agent ADC from Magenta, without the use of chemotherapy or radiation. These unprecedented results validate and advance Magentas conditioning platform.

Building on this work, Magentas new clinical candidate, MGTA-117, is a CD117 antibody conjugated to amanitin. Results published today in an abstract for the Transplant and Cellular Therapy annual meeting show that MGTA-117 potently depleted stem and progenitor cells and demonstrated a wide tolerability: potency ratio of 30 fold (therapeutic index; typical range for approved ADCs at this stage is two to six fold). This program is advancing to the clinic and further validates Magentas antibody drug conjugate-based conditioning platform. MGTA-117 was developed under a partnership with Heidelberg Pharma that grants Magenta exclusive worldwide development and marketing rights for ADCs using an amanitin payload and targeting CD117.

MGTA-117 in 2020

Magenta is scaling up manufacturing of MGTA-117 and completing IND-enabling studies in 2020. The Company intends to move this new product candidate into the clinic with initial clinical data expected in 2021.

CD45-ADC Recent Progress

Current standard treatment for patients with multiple sclerosis involves years of chronic dosing of medications that do not halt the progression of the disease. For patients with systemic sclerosis, a potentially fatal autoimmune disease, there are no approved therapies. Immune reset through stem cell transplant has demonstrated durable remissions in thousands of patients with autoimmune diseases such as multiple sclerosis and systemic sclerosis, and it is recommended by the European League Against Rheumatism (EULAR) in treatment guidelines for systemic sclerosis. The immune reset process involves two main steps: removing the disease-causing cells and replacing them with healthy cells to rebuild the immune system to a healthy state.

Magenta is developing targeted ADCs designed to precisely remove the disease-causing cells in the body without the need for chemotherapy or radiation. Magentas CD45-ADC program targets CD45, a protein expressed on immune cells and stem cells and is designed to remove the cells that cause autoimmune diseases in order to enable curative immune reset.

Story continues

Data presented at the American College of Rheumatology (ACR) meeting in November 2019 showed that a single dose of CD45-ADC removed disease-causing reactive T cells, enabled successful immune reset and rebuild of the immune system and was well tolerated in three models of autoimmune disease, including the EAE model, the most reliable murine model of multiple sclerosis. Further, a single dose of CD45-ADC significantly reduced disease incidence and delayed disease onset in this model that has successfully provided preclinical proof of concept for many clinically validated standard-of-care therapies.

CD45-ADC in 2020

Magenta has identified a lead antibody and has progressed this program into IND-enabling studies, which the Company plans to further advance in 2020.

MGTA-145 First-Line Stem Cell Mobilization Therapy

MGTA-145 Recent Progress

Magenta is developing MGTA-145 as the new first-line standard of care for stem cell mobilization in a broad range of diseases, including autoimmune diseases, blood cancers and genetic diseases. MGTA-145, a CXCR2 agonist, works in combination with plerixafor, a CXCR4 antagonist, to harness the physiological mechanism of stem cell mobilization.

Magenta is currently studying MGTA-145 and plerixafor in a Phase 1 study in healthy volunteers. Data from the Phase 1 study presented at the ASH annual meeting in December 2019 showed that MGTA-145 in combination with plerixafor successfully enables safe, same-day dosing, mobilization and collection of sufficient high-quality hematopoietic stem cells for transplant. Further, when cells collected from the first two apheresis subjects were transplanted into humanized mice, the cells engrafted more rapidly and at a five-fold higher level than cells from G-CSF-mobilized peripheral blood.

MGTA-145 in 2020

Magenta intends to complete the Phase 1 study and move this program into multiple Phase 2 studies in patients in 2020. The Phase 2 studies will include both allogeneic and autologous transplant settings and will evaluate mobilization and collection of high-quality cells and engraftment of the cells after transplant.

MGTA-456 Cell Therapy

MGTA-456 Recent Progress

MGTA-456 is a cell therapy designed to provide a high dose of stem cells that are well matched to the patient to enable safe immune and blood system rebuild and durable remissions in patients with blood cancers. In September, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation for MGTA-456 for the treatment of multiple inherited metabolic disorders.

Magenta is currently studying MGTA-456 in a Phase 2 study in patients with inherited metabolic disorders, including cerebral adrenoleukodystrophy (cALD) and Hurler syndrome. These are rare, rapidly progressive neurologic disorders that are fatal when left untreated. Results in the first two evaluable patients with cALD updated in December 2019 showed early and durable resolution of the disease at 12 months follow-up. The Loes score and NFS score, which measure progress of the disease, remained stable, suggesting that progress of the disease has been halted in these patients. The early and durable resolution of disease with MGTA-456 is not consistently seen with other therapies, including standard stem cell transplant, gene therapy or enzyme replacement therapy.

MGTA-456 in 2020

Magenta intends to complete enrollment in the Phase 2 in 2020 and continue dialogue with the FDA under the RMAT designation, and to discuss with the European Medicines Agency (EMA) for development in Europe

About Magenta Therapeutics

Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to allow more patients to receive one-time, curative therapies by making the process more effective, safer and easier.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "will," "could", "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption "Risk Factors" in Magentas Annual Report on Form 10-K, as updated by Magentas most recent Quarterly Reports on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200113005308/en/

Contacts

Magenta Therapeutics:Manisha Pai, Vice President, Communications & Investor Relations617-510-9193mpai@magentatx.com

Read more here:
Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals - Yahoo Finance

AgeX Therapeutics to Participate at Four Conferences in January 2020 – Yahoo Finance

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that the company will present at the following four conferences this month: Biotech Showcase, January 13-15; Precision Medicine World Conference (PMWC 2020), January 21-24; World Stem Cell Summit, January 21-24; and Longevity Therapeutics, January 28-30.

Details of the companys presentations follow:

Biotech Showcase January 13-15 at the Hilton San Francisco Union Square, San Francisco, CaliforniaAgeX session: Wednesday, January 15, 9:00am PST.

AgeXs founder and CEO Michael D. West, PhD will deliver a presentation on AgeX and its programs at this investor conference held concurrently with the J.P. Morgan Healthcare Conference.

World Stem Cell Summit January 21-24 at the Hyatt Regency Miami, Miami, Florida.

AgeX will participate in a 90-minute session that will include two talks as well as a panel discussion, on Thursday, January 23, 1:45-3:15pm EST. Dr. West will deliver a 25-minute presentation, "Towards safe in vivo partial reprogramming with induced tissue regeneration" while AgeXs VP, Discovery Research, Dana Larocca, PhD, will deliver a presentation, "Derivation and uses of highly pure, non-immunogenic lineage-specific stem cell lines."

Additionally, three AgeX team members will participate on a panel discussion, "The next stem cell revolution: transcending limits on purity, immunogenicity and oncogenicity." Panel participants include Drs. West and Larocca, in a session moderated by Dr. Aubrey de Grey, AgeXs VP, New Technology Discovery.

Precision Medicine World Conference (PMWC 2020) January 21-24 at the Santa Clara Convention Center, Santa Clara, CaliforniaAgeX Session: Thursday, January 23, 3:30pm PST.

AgeXs CFO Russell Skibsted will deliver a corporate presentation as part of the Emerging Therapeutics Track.

Longevity Therapeutics January 28-30 at the Holiday Inn Golden Gateway Hotel, San FranciscoAgeX session: Wednesday, January 29, 1:30pm PST.

Dr. Larocca will deliver a presentation on AgeXs induced tissue regeneration (iTR) program.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates" should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the "Risk Factors" section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005342/en/

Contacts

Media Contact for AgeX:

Bill Douglass Gotham Communications, LLCbill@gothamcomm.com (646) 504-0890

See original here:
AgeX Therapeutics to Participate at Four Conferences in January 2020 - Yahoo Finance

Imber Medical has what we’ve all been waiting for – Brunswick News

The word enthusiasm comes to mind when you meet Dr. Slack, MD and her team. Even the building itself has an air of newness and excitement. Dr. Slack begins to tell me about what is available at Imber and Im surprised that I have never heard of several of these treatments.

I see her face light up as she explains how much these treatments have helped people. And that for some, aesthetics treatments can be better than Prozac! The latest treatment acquired is the EMSCULPT. This is a machine that uses magnetic energy to initiate contractions of the muscles 20,000 contractions in 30 minutes to be exact!

This leads to formation of new muscle fibers and improvement in core strength that continues for years! Studies show that EMSCULPT not only increases muscles but induces 20% fat reduction (as a glorious side effect). These results have been confirmed by MRIs so there is no guesswork as to the devices effectiveness. What is amazing about this machine is that you get the benefits of doing 20,000 sit-ups while lying down and relaxing. No sweating, no pain, no shortness of breath or increase in heart rate.

This is a fantastic option for anyone who has trouble building up their muscles because of time constraints, back pain, child- birth or even hitting that dreaded plateau at the gym. Ladies love the flat stomachs, toned abs and improvements in physical ability appreciated during yoga, pilates, and tennis! Men have become huge fans after seeing how the results of strengthening ones core affects their golf game!

We first realized there was a demand for EMSCULPT in the Golden Isles when several existing clients expressed how much it had helped their back pain when treated with EMSCULPT at an Atlanta clinic says Dr. Slack. What sold our team was the before and after pictures which speak for themselves. But I was even more impressed with the data and shocked to learn that this device is the only non-surgical, FDA approved option for treatment for diastasis recti (the separation of stomach muscles that occurs during pregnancy). Life brings a lot of changes and how we look, and feel can greatly impact our confidence. What Imber offers is the latest solutions that are proven to work.

EMSCULPT is also FDA approved for building the muscles of the abs, glutes, arms and legs. I cant help but think that this is the perfect time of year. Valentines Day, and shorts season will be here before we know it!

Dr. Slack goes on to list other novel treatments. She shares with me information on Verju, a FDA approved, pain-free, non-surgical, fat reducing (non-hot, non- cold) laser. That consistently delivers results of 4 inch overall circumference reduction after just 6 treatments.

If that wasnt enough to blow my mind she went on to tell me about PDO Threads. She describes how these FDA approved threads can lift the face and smooth out wrinkles while building collagen. Plasma Pen was mentioned next. which is an FDA approved treatment for a non-surgical eyelid lift and wrinkle removal. PRP (Platelet Rich Plasma) is another option in the fight to revitalize the skin. Like the Plasma Pen, PRP is 100% natural and organic which is important to the Imber team!

Even the staples of aesthetics like Botox and filler treatments are taken to a whole new level. Dr. Slack is so proud of her team consisting of herself as an aesthetics board certified MD and advanced registered nurse practitioners. Imbers master injector, Bianca Trevino ARNP, is also board certified in aesthetics and able to provide Botox injections in areas I had never heard of! She can upturn the corners of a down turned mouth, lower the lip of a gummy smile, prevent the tip of a nose from pulling down, provide brow lifts, jaw definition, fine line and wrinkle reduction with micro-Botox and even eliminate neck bands! With regard to filler, the advanced training really shows with their results in providing a natural and youthful appearance, never looking overdone. Imber has virtually every toxin and filler available and the knowledge of what needs to be used when. Bioidentical hormone therapy, IV hydration therapy, hair restoration for men and women, intimacy treatments, jaw contouring, medical assisted weight loss, scar revision, acne treatment and so much more is offered at Imber.

When combining the above treatments with medical grade products (including stem cell and sun protection) sold at Imber: prevention, correction and maintenance are all optimized.

In finishing up my visit, Dr. Slack tells me Our clinics goal is to provide the latest FDA approved solutions available to help all of the Golden Isles look and feel like the best version of themselves. We are so blessed to be a part of this wonderful community and look forward to giving it the best the World has to offer.

If you would like to learn more, Imber hosts a Thirsty Thursday event every 3rd Thursday of the month for those who Thirst for Knowledge ...or wine! Join Imber Jan 16th to learn more about Emsculpt or any other services Imber offers!

Excerpt from:
Imber Medical has what we've all been waiting for - Brunswick News

Tacitus Therapeutics Launches in Collaboration with Mount Sinai to Develop Stem Cell Therapies for Life-Threatening Diseases – Yahoo Finance

Tacitus Therapeutics exclusively licenses technology for expansion, differentiation and engineering of hematopoietic stem cells for use in therapeutic applications

NEW YORK, Jan. 9, 2020 /PRNewswire/ -- Tacitus Therapeutics, a clinical-stage company, has launched in collaboration with the Mount Sinai Health System to develop stem cell therapies initially targeting blood cancers and related clotting disorders. Their first therapy, HSC100, currently is being investigated in a Phase I clinical trial1.

Tacitus is building upon technology developed by and exclusively licensed from Mount Sinai. Based on research by scientific co-founders Ronald Hoffman, M.D., and Camelia Iancu-Rubin, Ph.D., the technology includes proprietary cell expansion, differentiation and engineering methods. Together, these methods manufacture healthy cells that overcome the limitations of traditional allogeneic, or donor, cell transplantations.

Blood cancers comprise about 10% of new cancer cases in the U.S. each year, and almost 60,000 people die from blood cancer complications annually. Most blood cancers start in the bone marrow, where blood is produced. A common therapy for such blood cancers is a hematopoietic stem cell (HSC) treatment or, as more commonly referred to, bone marrow transplantation. In this process, doctors infuse healthy HSCs into the patient's bloodstream, where they migrate to the bone marrow to grow or engraft.

HSCs for this process can be collected from bone marrow, circulating blood, or umbilical cord blood (CB) of healthy donors. While HSC transplants are common, significant barriers to success exist, including high levels of graft-versus-host disease, low numbers of healthy cells obtained from CB, and increased risk of bleeding due to delayed megakaryocyte, or platelet, engraftment.

Hoffman and Iancu-Rubin are pioneers of bone marrow cell therapy treatments, and development of this technology was enabled by the New York State Stem Cell Science program, NYSTEM. As a New York State Department of Health initiative, NYSTEM awarded a $1 million grant to Hoffman in 2010 that supported the original research underpinning this platform technology. In 2015, NYSTEM awarded Hoffman and Iancu-Rubin an $8 million grant to translate the technology from the laboratory into the clinic, where it is currently in clinical trial1.

Hoffman also serves as Director of the Myeloproliferative Disorders Research Program and Professor of Medicine (Hematology and Medical Oncology) and Iancu-Rubin is Associate Professor of Pathology at the Icahn School of Medicine and Director of the Cellular Therapy Laboratory at Mount Sinai Hospital.

"Promising discoveries by Mount Sinai scientific thought leaders may lead to new, essential cell-based therapies that will broadly benefit patients," said Erik Lium, Executive Vice President and Chief Commercial Innovation Officer, Mount Sinai Innovation Partners. "We're pleased to be collaborating with Tacitus to launch the next stage of development for these technologies."

"Tacitus is committed in its mission to advance next-generation cell therapies with curative potential," said Carter Cliff, CEO of Tacitus. "Based on our founders' solid foundation of research, we are translating these discoveries into broad clinical practice as we look to dramatically improve the standard of care for patients with life-threatening conditions."

About HSC100

HSC100 is an investigational therapy based on allogeneic hematopoietic stem cells (HSC) expanded from umbilical cord blood. HSC100 is being investigated currently in an open-label Phase I clinical trial1 in the United States for treatment of hematological malignancies. The success of unmanipulated cord blood as a source of stem cells has been hampered by the small number of stem cells present in a single cord, leading to delayed engraftment and frequent graft failure. Our proprietary technology includes the use of an epigenetic modifier, valproic acid, to expand the number and the quality of HSCs found in cord blood collections. For more information on HSC100 clinical trials, please visit http://www.clinicaltrials.gov.

1ClinicalTrials.gov identifier NCT03885947.

About Tacitus Therapeutics

Tacitus Therapeutics is a clinical-stage biotechnology company developing advanced medicines for treatment of blood cancers, immune disorders and other intractable disease conditions. Our mission is to pioneer best-in-class therapies using proprietary cell expansion, differentiation and engineering platform technologies that overcome the limitations of traditional cell transplantation. Initial targets include a lead clinical program (HSC100) investigating the treatment of blood cancers, followed by preclinical programs to address clotting disorders and other serious unmet medical needs. For additional information, please visit http://www.tacitustherapeutics.com.

Story continues

About Mount Sinai Health System

The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Gynecology, Nephrology, Neurology/Neurosurgery, and Orthopedics in the 2019-2020 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology, Mount Sinai St. Luke's and Mount Sinai West are ranked 23rd nationally for Nephrology and 25th for Diabetes/Endocrinology, and Mount Sinai South Nassau is ranked 35th nationally for Urology. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and Mount Sinai South Nassau are ranked regionally. For more information, visit http://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

About Mount Sinai Innovation Partners (MSIP)

MSIP is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into health care products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, please visit http://www.ip.mountsinai.orgor find MSIP onLinkedIn, Twitter, Facebook,Medium, and YouTube.

Media Contacts:

Mount Sinai Cynthia Cleto Mount Sinai Innovation Partners (646) 605-7359 cynthia.cleto@mmsm.edu

Tacitus TherapeuticsJoleen RauRau Communications(608) 209-0792232130@email4pr.com

View original content:http://www.prnewswire.com/news-releases/tacitus-therapeutics-launches-in-collaboration-with-mount-sinai-to-develop-stem-cell-therapies-for-life-threatening-diseases-300984051.html

SOURCE Tacitus Therapeutics

See more here:
Tacitus Therapeutics Launches in Collaboration with Mount Sinai to Develop Stem Cell Therapies for Life-Threatening Diseases - Yahoo Finance